SOUTH SAN FRANCISCO, CA--(Marketwire - September 26, 2007) - Novacea, Inc. (NASDAQ: NOVC) today announced that the company has initiated a randomized, placebo-controlled, multicenter Phase 2 trial of Asentar™ (DN-101) in patients with advanced pancreatic adenocarcinoma. Asentar is the company’s lead investigational product and is also currently in a Phase 3 clinical trial for the treatment of patients with advanced prostate cancer.
